On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

Morgan Stanley upgraded U.S. Bancorp (USB) to Overweight from Equal Weight with a price target of $57, up from $54. The firm ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

The man charged with attempting to assassinate Donald Trump after allegedly positioning himself with a rifle outside one of the former president's Florida golf courses on Sept. 15 pleaded not ...

Their stories come as the county is undergoing a public reckoning over child welfare policies ...